Trial Profile

Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diroximel-fumarate (Primary) ; Interferon beta-1a (Primary) ; Natalizumab (Primary)
Indications Multiple sclerosis
Focus Adverse reactions
Sponsors Biogen

Most Recent Events

08 Dec 2023 Planned number of patients changed from 454 to 908.
08 Dec 2023 Status changed from not yet recruiting to recruiting.
23 Mar 2023 Planned initiation date changed from 20 Jan 2023 to 30 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com